CFM
NKTR icon

Compass Financial Management’s Nektar Therapeutics NKTR Stock Holding History

Compass Financial Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73 Buy
+1
New +$73 ﹤0.01% 1516

Other funds holding NKTR

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Compass Financial Management's NKTR Position: Q2 2026 in Review

Compass Financial Management opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 1 share worth $73. The stake represents ﹤0.01% of the portfolio and ranks #1516 among its holdings.

219 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Compass Financial Management held 1 share of Nektar Therapeutics worth $73 as of Q2 2026.
  • Nektar Therapeutics was a new Compass Financial Management position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Compass Financial Management's portfolio in Q2 2026, its #1516 holding.
  • 219 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Compass Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.